ResMed (RMD) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $34.19B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Michael J. Farrell |
| IPO Date | 1995-06-02 | CAGR | 22.14% |
| Employees | 11,370 | Website | www.resmed.com |
| Div. Yield | 0.46% | Payout Ratio | 40% |
| Buy Back Yield | 1.56% | Total Yield | 2.02% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $31.35B | P/E | 21.88 | Forward P/E | 17.9 | PEG | 9.28 |
| P/S | 13.64 | P/B | 11.81 | P/CF | 24.65 | P/FCF | 26.66 |
| Sales | $5.65B | Sales 1Y | 9.85% | Sales 3Y | 33.87% | Sales 5Y | 76.85% |
| EPS | $10.77 | EPS 1Y | 6.52% | EPS 3Y | 66.07% | EPS 5Y | 212.65% |
| Sales QoQ | 2.25% | EPS QoQ | -12.55% | Sales QoQ Avg | 2.12% | EPS QoQ Avg | -1.62% |
| Gross Margin | 61.06% | Operating Margin | 33.48% | Profit Margin | 26.94% | ROCE | 25% |
| ROA | 17% | ROE | 24% | Altman Z Score | 11.8 | Piotroski Score | 6 |
| Current Ratio | 3.1 | Quick Ratio | 2.42 | Cash Ratio | 1.05 | Op. CF Ratio | 1.29 |
| Debt/Equity | 0.13 | Debt/Assets | 0.09 | Lt Debt/Equity | 0.08 | Lt Debt/Cap. | 0.08 |
| Intrst Cov. | 37.92 | Inventory Turnover | 2.33 | Asset Turnover | 0.63 | Receivables Turnover | 5.46 |
| Enterprise Value | $31.35B | P/E Ratio | 21.88 |
| Forward P/E | 17.9 | PEG Ratio | 9.28 |
| P/S Ratio | 13.64 | P/B Ratio | 11.81 |
| P/CF Ratio | 24.65 | P/FCF Ratio | 26.66 |
| EPS | $10.77 | EPS Growth 1Y | 6.52% |
| EPS Growth 3Y | 66.07% | EPS Growth 5Y | 212.65% |
| Revenue Growth 1Y | 9.85% | Gross Margin | 0.61% |
| Operating Margin | 0.33% | Profit Margin | 0.27% |
| ROE | 0.24% | ROA | 0.17% |
| ROCE | 0.25% | Current Ratio | 3.1 |
| Quick Ratio | 2.42 | Cash Ratio | 1.05 |
| Debt/Equity | 0.13 | Interest Coverage | 37.92 |
| Altman Z Score | 11.8 | Piotroski Score | 6 |
ResMed (RMD) valuation & financials
ResMed (RMD) has a market capitalization of $34.19B and trades at a price-to-earnings ratio of 21.9. It operates in the Healthcare sector (Medical - Devices).
ResMed's revenue grew +9.9% over the last year.
ResMed's next earnings report is scheduled for October 29, 2026 after market close; analysts estimate EPS of $2.69. Check the earnings calendar to see all companies reporting this week.
ResMed (RMD) — frequently asked questions
When does ResMed (RMD) report earnings next?
ResMed is expected to report earnings on October 29, 2026 after market close. Analysts estimate EPS of $2.69.
What is ResMed's market cap?
ResMed (RMD) has a market capitalization of $34.19B.
What is RMD's P/E ratio?
ResMed trades at a price-to-earnings ratio of 21.9, with trailing twelve-month EPS of $10.77.
How fast is ResMed growing?
ResMed's revenue grew +9.9% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)